Milestone Pharmaceuticals Stock (NASDAQ:MIST)
Previous Close
$1.70
52W Range
$1.12 - $3.52
50D Avg
$1.56
200D Avg
$1.56
Market Cap
$92.79M
Avg Vol (3M)
$253.40K
Beta
1.73
Div Yield
-
MIST Company Profile
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
MIST Performance
Peer Comparison
| Ticker | Company |
|---|---|
| NLTX | Neurogene Inc. |
| SPRO | Spero Therapeutics, Inc. |
| IVA | Inventiva S.A. |
| HOOK | HOOKIPA Pharma Inc. |
| CHRS | Coherus BioSciences, Inc. |
| SCPH | scPharmaceuticals Inc. |
| MCRB | Seres Therapeutics, Inc. |
| LIFE | aTyr Pharma, Inc. |
| DMAC | DiaMedica Therapeutics Inc. |
| ONCY | Oncolytics Biotech Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| GRCL | Gracell Biotechnologies Inc. |